Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer et al. (Fri,) studied this question.

www.synapsesocial.com/papers/69d94c0e00ab073a27835e4f — DOI: https://doi.org/10.1056/nejmoa1510665

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial· 2014 · 1,074 citations
2. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).· 2015 · 147 citations
3. Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma· 2004 · 802 citations
4. Molecular mechanisms of T‐cell tolerance· 2011 · 89 citations
5. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes.· 2015 · 26 citations